ArticleClinical and translational science2026
CYP2D6 Metabolizer Status and Mortality in Metoprolol Users.
Article in Clinical and translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Numerous pharmacogenomic (PGx) associations of pharmacokinetics and pharmacodynamics of commonly prescribed medications have been reported. Yet, the evidence supporting their association on survival remains underexamined. We sought to investigate the CYP2D6-metoprolol association and determine whether the established variability in drug exposure and hemodynamic response would translate into differences in mortality across metabolizer status in the Montreal Heart Institute Hospital Cohort. Single random plasma samples were collected from 996 patients receiving metoprolol tartrate. Bioanalytical quantification was performed via liquid chromatography-tandem mass spectrometry, while CYP2D6 metabolizer status was based on standardized classifications. Cox regression models adjusted for age, sex, cardiovascular history, concomitant medications, and CYP2D6 inhibitors were used to assess the time to death since enrolment. Overall, 24.3% (n = 242) of patients were deceased at follow-up (median 101.4 months). Higher metabolizer status at CYP2D6 was associated with lower risk of death (HR = 0.82, 95% CI: 0.67-0.99; p = 0.04). Metoprolol concentrations were no longer associated with mortality after adjusting for possible confounders. Our study suggests that CYP2D6-inferred metabolizer status can inform on mortality risk in patients treated with metoprolol. Larger initiatives are required to confirm the association of CYP2D6 metabolizer status with clinical events beyond pharmacokinetic and hemodynamic considerations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.